Salix Announces 2023 Gastrointestinal Health Scholars Program Winners

For Fourth Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 Scholarship

Bausch Health Companies Inc. (NYSETSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced the winners of its 2023 Salix Gastrointestinal Health Scholars Program. For the fourth consecutive year, Salix will be awarding $10,000 each to 10 students living with a GI disease

"At Salix, we understand it can be incredibly difficult to balance both the pursuit of higher education and the challenges associated with living with a gastrointestinal condition," said Nicola Kayel, vice president, Marketing, Salix. "That is why Salix is dedicated to reducing the stress and financial burden for these students. We congratulate this year's 10 scholarship recipients for whom we are proud to support in the advancement of their academic goals."

The 2023 awardees were selected from more than 225 applications. As part of the process, applicants were required to submit essays describing how their GI condition has impacted their educational journey, as well as delve into the role their health care provider played in helping them reach their personal and educational goals. All scholarship applications were reviewed by an independent panel of judges.

The Salix Gastrointestinal Health Scholars Program recognizes students across a wide range of educational pursuits, with scholarships in four categories, including the Undergraduate Scholar Awards, for those pursuing undergraduate degrees; the Graduate Scholar Awards, for those pursuing graduate degrees; the Working Parent's Scholar Award, for parents pursuing undergraduate, vocational/technical or graduate degrees, and the Single Parent's Scholar Award, for students who are single parents pursuing undergraduate, vocational/technical, or graduate degrees.

The 2023 Salix Gastrointestinal Health Scholars Program recipients are:

  • Undergraduate Scholar Awards
    • Kate Paden, Colorado Springs, CO - Creighton University
    • Alexander Myers, San Diego, CA - Northwestern University
    • Charlie Harker, Lebanon, OH - University of Cincinnati
    • Lena Stoltzfus, Tucson, AZ - Haverford College
  • Graduate Scholar Awards
    • Kaitlyn Mi, Brentwood, TN - Vanderbilt University School of Medicine
    • Emmanuel Dean, Stone Mountain, GA - Morehouse School of Medicine
    • Caroline Casola, Orlando, FL - Washington University in St. Louis School of Law
    • Raina Levin, Jamaica Plain, MA - Boston University School of Public Health
  • Working Parent's Scholar Award
    • Juanita Ramirez, Edinburg, TX - University of Texas Rio Grande Valley
  • Single Parent Scholar Award
    • Kimberly Sperry, Mesquite, TX - Texas Women's University

"I am so grateful to have been selected for this generous scholarship which allows me to continue pursuing my higher education goals," said a 2022 scholarship recipient. "Receiving this honor has empowered me to view the world as one where I am not limited by my disease."

To learn more about the Salix Gastrointestinal Health Scholars Program, visit www.salix.com/scholarship.

About Salix

Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases. For more than 30 years, Salix has licensed, developed and marketed innovative products to improve patients' lives and arm health care providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists and primary care. Salix is headquartered in Bridgewater, New Jersey. For more information about Salix, visit www.Salix.com and connect with us on Twitter and LinkedIn.

About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling ownership of Bausch + Lomb Corporation. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn.

Investor Contact:

Mark Maico
ir@bauschhealth.com
(877) 281-6642 (toll-free)

Media Contact:

Kevin Wiggins
corporate.communications@bauschhealth.com
(908) 541-3785

SOURCE: Salix Pharmaceuticals



View source version on accesswire.com:
https://www.accesswire.com/766631/Salix-Announces-2023-Gastrointestinal-Health-Scholars-Program-Winners

News Provided by ACCESSWIRE via QuoteMedia

BHC:CA,BHC
The Conversation (0)
Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today announced that they will be presenting data from its Phase 2 trial evaluating Amiselimod as treatment for active ulcerative colitis (UC). The data will be presented at Digestive Disease Week (DDW) 2024 during the IMIBD Late Breakers and Innovations in IBD session on Sunday, May 19, 2024, in Washington, D.C

"We are pleased to present late-breaking data on Amiselimod, our investigational, oral, sphingosine 1-phosphate (S1P) receptor modulator as a potential treatment for the induction of remission in UC," said Tage Ramakrishna, M.D., Chief Medical Officer and President of Research & Development, Bausch Health. "The abstract underscores our steadfast commitment to developing new and innovative therapies for patients with UC."

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Bausch Health Announces Updates Related to Norwich XIFAXAN Matters

Bausch Health Announces Updates Related to Norwich XIFAXAN Matters

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business Salix Pharmaceuticals, today announced certain updates related to its litigation with Norwich Pharmaceuticals, Inc

With respect to the April 11, 2024, decision of the US Court of Appeals for the Federal Circuit, both Bausch Health and Norwich have filed petitions for panel rehearing or rehearing en banc. The Company anticipates a decision on whether a rehearing will be granted within the next three months.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×